Serine/threonine kinase receptors are the TGF-β superfamily's membrane gates: type-II and type-I receptor pairs whose cytoplasmic kinases phosphorylate serine and threonine — on each other, then on SMAD proteins — to carry instructions for growth arrest, differentiation, extracellular matrix, and immune suppression. Where tyrosine-kinase receptors say "grow," this family most often says "stop" — which is why its pathway is a tumor suppressor early in cancer (mutated out) and a metastasis promoter late (redeployed).
Ligand (with type III receptors presenting), SMAD2/3/1/5/8, endoglin
Structure
Type-I receptors carry the GS domain — a short serine-glycine repeat that type-II phosphorylates to unleash the type-I kinase; the pair's order-of-operations is the family's signature.
Ligand (a cystine-knot dimer) clamps the type-I/type-II pair into the signalling complex; accessory receptors (betaglycan, endoglin) concentrate ligand at the membrane.
FKBP12 binds unliganded type I receptors and blocks the GS domain — the safety catch that ligand binding releases.
Function
SMAD signalling: receptor-phosphorylated R-SMADs (2/3 for TGF-β-activin; 1/5/8 for BMP) complex with SMAD4 and enter the nucleus — the direct transcriptional wire from membrane to DNA, see MAPK for the parallel wires.
Growth arrest: TGF-β induces CDK inhibitors — p15 (a relative of p16) and p21 — and represses Myc — epithelial cells' cytostatic response, the tumor-suppressor face.
Developmental patterning: BMP gradients pattern bone, cartilage, and the embryo's axes — BMP signalling's morphogen mathematics.
Regulation
Inhibitory SMADs (6, 7) and the E3 ligase Smurf2 degrade receptors — the pathway's negative feedback.
Phosphatase and pseudoreceptor (BAMBI) dampen; ligand traps (noggin, chordin for BMPs) shape gradients extracellularly — the developmental tuning layer.
Non-SMAD branches (MAPK, PI3K, RhoA) run in parallel — the same receptor, context-dependent output.
Interactions
With regulatory T cells: TGF-β and IL-10's tolerance programs use the receptor's SMAD arm — immune suppression's inside lane.
With matrix: TGF-β drives collagen and fibronectin transcription — fibrosis's central axis.
With cancer staging: receptor loss or SMAD4 deletion (pancreatic cancer's classic) removes the brake; later reactivation drives EMT and metastasis — one pathway, two roles by stage.
Oncology: TGF-β blockade in metastasis and checkpoint-resistance trials — the pathway's late-stage reemployment targeted with antibodies and small molecules.
Fibrosis: kidney, liver, and lung fibrosis programs center on TGF-β signalling — antifibrotic therapy's biggest single target.